Danaher Corporation

DHR Healthcare Diagnostics & Research

Danaher Corporation’s revenue for fiscal 2025 (year ended December 2025) was $24.6 billion, up 2.90% from fiscal 2024. In the quarter to June 2026, revenue grew 5.54%, EPS grew 59.7%, free cash flow grew 15.6% and total debt rose 49.2%, each against the same quarter a year earlier. Member of the S&P 500.

228.97 2.53 −1.09%
Market cap
$162.7B
P/E
40.5×
Fwd P/E
29.2×
Dividend yield
0.66%
F-score
6/9
Altman Z
4.52
Beneish M
−2.57
Dividend safety
69/100
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
33.71 36.53 45.15 40.63

+8 more quarters

P/S ratio
5.35 5.42 6.64 5.81
P/FCF ratio
24.48 25.24 30.82 28.02
P/Operating CF
87.58 101.53 77.07 84.78
P/B ratio
2.55 2.53 3.11 2.76
EV/Sales
6.18 5.90 7.20 6.44
EV/EBITDA
20.14 20.17 24.79 22.21
EV/FCF
28.26 27.47 33.43 31.07
Current Ratio
1.65 1.87 1.87 1.52
Net Debt/EBITDA
11.35 6.02 6.49 8.62
Debt/Equity
0.48 0.33 0.35 0.33
Earnings Yield
2.97% 2.74% 2.21% 2.46%
Free Cash Flow Yield
4.09% 3.96% 3.24% 3.57%
Free Cash Flow per Share
1.79 1.53 2.48 1.93
Book value per Share
74.57 74.81 73.72 71.87
Free Cash Flow
1,265.00 1,085.00 1,769.00 1,370.00
EV/EBIT
30.26 30.69 37.73 33.86
Other line items

Show all line items

Columns are period end dates